SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-258568
Filing Date
2024-11-14
Accepted
2024-11-14 16:08:01
Documents
15
Period of Report
2024-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d912402d8k.htm   iXBRL 8-K 25472
2 EX-99.1 d912402dex991.htm EX-99.1 35049
6 GRAPHIC g912402g1114202521365.jpg GRAPHIC 3027
  Complete submission text file 0001193125-24-258568.txt   197526

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA alrn-20241114.xsd EX-101.SCH 2858
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE alrn-20241114_lab.xml EX-101.LAB 18759
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alrn-20241114_pre.xml EX-101.PRE 11716
18 EXTRACTED XBRL INSTANCE DOCUMENT d912402d8k_htm.xml XML 3808
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Aileron Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

IRS No.: 134196017 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38130 | Film No.: 241462082
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)